Skip to main content

Deciphera DCC-3014-02-001: A Phase 2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, PK, and Efficacy of Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy

Clinical Trial Grant
Duke Scholars

Awarded By

Deciphera Pharmaceuticals, LLC

Start Date

October 3, 2025

End Date

September 28, 2030
 

Awarded By

Deciphera Pharmaceuticals, LLC

Start Date

October 3, 2025

End Date

September 28, 2030